Craven House Capital (GB:CRV) has released an update.
Craven House Capital PLC has announced a significant update on its investment in Bio Vitos Medical Limited, indicating an allocation of approximately 63.6 million shares in Bio Vitos Pharma AB, resulting in a 15.4% ownership post-transaction. After selling a portion of the shares to cover related costs, Craven House retains a 15.4% share in the listed Swedish medical technology company, in addition to maintaining a 24.5% shareholding in Bio Vitos Medical Limited. This transaction enhances Craven House’s investment portfolio in the technology sector.
For further insights into GB:CRV stock, check out TipRanks’ Stock Analysis page.
